Brian Halak is a Managing Partner at Medical Excellence Capital (MEC). Prior to joining MEC, Brian was a Partner at Domain Associates where he invested in over a dozen companies including Esprit Pharma (acquired by Allergan), Dicerna Therapeutics (Nasdaq: DRNA), Tobira Therapeutics (acquired by Allergan), Alimera Sciences (Nasdaq: ALIM), and Vanda Pharmaceuticals (Nasdaq: VNDA). Brian also established and directed Domain’s prior initiatives in China. During his time as Domain, he also formed companies with scientific founders from leading academic institutions. Previously, Brian was an associate with Advanced Technology Ventures where he participated in the firm’s investments in Plexxikon, Percardia and Emphasys. Brian received his B.S.E. in bioengineering from the University of Pennsylvania and his Ph.D. in immunology from Thomas Jefferson University.
